Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries

Background Systemic lupus erythematosus (SLE) is characterised by increased cardiovascular morbidity and mortality risk. We aimed to examine the prevalence of traditional cardiovascular risk factors and their control in an international survey of patients with systemic lupus erythematosus. Methods I...

Full description

Autores:
Bolla, Eleana
Semb, Anne Grete
Kerola, Anne M.
Ikdahl, Eirik
Petri, Michelle
Pons-Estel, Guillermo J.
Karpouzas, George A.
Sfikakis, Petros P.
Quintana, Rosana
Prasanna Misra, Durga
Ferreira Borba, Eduardo
Garcia-de la Torre, Ignacio
Popkova, Tatiana V.
Artim-Esen, Bahar
Troldborg, Anne
Fragoso-Loyo, Hilda
Ajeganova, Sofia
Yazici, Ayten
Aroca-Martinez, Gustavo
Direskeneli, Haner
Ugarte-Gil, Manuel F.
Mosca, Marta
Goyal, Mohit
Svenungsson, Elisabet
Macieira, Carla
Hoi, Alberta
Lerang, Karoline
Costedoat-Chalumeau, Nathalie
Tincani, Angela
Mirrakhimov, Erkin
Acosta Colman, Isabel
Danza, Alvaro
Massardo, Loreto
Blagojevic, Jelena
Yılmaz, Neslihan
Tegzová, Dana
Yavuz, Sule
Korkmaz, Cengiz
Hachulla, Eric
Moreno Alvarez, Mario J.
Muñoz-Louis, Roberto
Pantazis, Nikos
Tektonidou, Maria G.
behalf of the SURF-SLE and APS
Tipo de recurso:
Fecha de publicación:
2024
Institución:
Universidad Simón Bolívar
Repositorio:
Repositorio Digital USB
Idioma:
eng
OAI Identifier:
oai:bonga.unisimon.edu.co:20.500.12442/14939
Acceso en línea:
https://hdl.handle.net/20.500.12442/14939
https://www.sciencedirect.com/science/article/abs/pii/S2665991324000900?via%3Dihub
Palabra clave:
Rights
openAccess
License
Attribution-NonCommercial-NoDerivs 3.0 United States
id USIMONBOL2_86c0ebcbcdcd5d2f91bc53c0a6989be1
oai_identifier_str oai:bonga.unisimon.edu.co:20.500.12442/14939
network_acronym_str USIMONBOL2
network_name_str Repositorio Digital USB
repository_id_str
dc.title.eng.fl_str_mv Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
title Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
spellingShingle Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
title_short Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
title_full Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
title_fullStr Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
title_full_unstemmed Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
title_sort Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
dc.creator.fl_str_mv Bolla, Eleana
Semb, Anne Grete
Kerola, Anne M.
Ikdahl, Eirik
Petri, Michelle
Pons-Estel, Guillermo J.
Karpouzas, George A.
Sfikakis, Petros P.
Quintana, Rosana
Prasanna Misra, Durga
Ferreira Borba, Eduardo
Garcia-de la Torre, Ignacio
Popkova, Tatiana V.
Artim-Esen, Bahar
Troldborg, Anne
Fragoso-Loyo, Hilda
Ajeganova, Sofia
Yazici, Ayten
Aroca-Martinez, Gustavo
Direskeneli, Haner
Ugarte-Gil, Manuel F.
Mosca, Marta
Goyal, Mohit
Svenungsson, Elisabet
Macieira, Carla
Hoi, Alberta
Lerang, Karoline
Costedoat-Chalumeau, Nathalie
Tincani, Angela
Mirrakhimov, Erkin
Acosta Colman, Isabel
Danza, Alvaro
Massardo, Loreto
Blagojevic, Jelena
Yılmaz, Neslihan
Tegzová, Dana
Yavuz, Sule
Korkmaz, Cengiz
Hachulla, Eric
Moreno Alvarez, Mario J.
Muñoz-Louis, Roberto
Pantazis, Nikos
Tektonidou, Maria G.
behalf of the SURF-SLE and APS
dc.contributor.author.none.fl_str_mv Bolla, Eleana
Semb, Anne Grete
Kerola, Anne M.
Ikdahl, Eirik
Petri, Michelle
Pons-Estel, Guillermo J.
Karpouzas, George A.
Sfikakis, Petros P.
Quintana, Rosana
Prasanna Misra, Durga
Ferreira Borba, Eduardo
Garcia-de la Torre, Ignacio
Popkova, Tatiana V.
Artim-Esen, Bahar
Troldborg, Anne
Fragoso-Loyo, Hilda
Ajeganova, Sofia
Yazici, Ayten
Aroca-Martinez, Gustavo
Direskeneli, Haner
Ugarte-Gil, Manuel F.
Mosca, Marta
Goyal, Mohit
Svenungsson, Elisabet
Macieira, Carla
Hoi, Alberta
Lerang, Karoline
Costedoat-Chalumeau, Nathalie
Tincani, Angela
Mirrakhimov, Erkin
Acosta Colman, Isabel
Danza, Alvaro
Massardo, Loreto
Blagojevic, Jelena
Yılmaz, Neslihan
Tegzová, Dana
Yavuz, Sule
Korkmaz, Cengiz
Hachulla, Eric
Moreno Alvarez, Mario J.
Muñoz-Louis, Roberto
Pantazis, Nikos
Tektonidou, Maria G.
behalf of the SURF-SLE and APS
description Background Systemic lupus erythematosus (SLE) is characterised by increased cardiovascular morbidity and mortality risk. We aimed to examine the prevalence of traditional cardiovascular risk factors and their control in an international survey of patients with systemic lupus erythematosus. Methods In this multicentre, cross-sectional study, cardiovascular risk factor data from medical files of adult patients (aged ≥18) with SLE followed between Jan 1, 2015, and Jan 1, 2020, were collected from 24 countries, across five continents. We assessed the prevalence and target attainment of cardiovascular risk factors and examined potential differences by country income level and antiphospholipid syndrome coexistence. We used the Systemic Coronary Risk Evaluation algorithm for cardiovascular risk estimation, and the European Society of Cardiology guidelines for assessing cardiovascular risk factor target attainment. People with lived experience were not involved in the research or writing process. Findings 3401 patients with SLE were included in the study. The median age was 43·0 years (IQR 33–54), 3047 (89·7%) of 3396 patients were women, 349 (10.3%) were men, and 1629 (48·1%) of 3390 were White. 556 (20·7%) of 2681 patients had concomitant antiphospholipid syndrome. We found a high cardiovascular risk factor prevalence (hypertension 1210 [35·6%] of 3398 patients, obesity 751 [23·7%] of 3169 patients, and hyperlipidaemia 650 [19·8%] of 3279 patients), and suboptimal control of modifiable cardiovascular risk factors (blood pressure [target of <130/80 mm Hg], BMI, and lipids) in the entire SLE group. Higher prevalence of cardiovascular risk factors but a better blood pressure (target of <130/80 mm Hg; 54·9% [1170 of 2132 patients] vs 46·8% [519 of 1109 patients]; p<0·0001), and lipid control (75·0% [895 of 1194 patients] vs 51·4% [386 of 751 patients], p<0·0001 for high-density lipoprotein [HDL]; 66·4% [769 of 1158 patients] vs 60·8% [453 of 745 patients], p=0·013 for non-HDL; 80·9% [1017 of 1257 patients] vs 61·4% [486 of 792 patients], p<0·0001 for triglycerides]) was observed in patients from high-income versus those from middle-income countries. Patients with SLE with antiphospholipid syndrome had a higher prevalence of modifiable cardiovascular risk factors, and significantly lower attainment of BMI and lipid targets (for low-density lipoprotein and non-HDL) than patients with SLE without antiphospholipid syndrome. Interpretation High prevalence and inadequate cardiovascular risk factor control were observed in a large multicentre and multiethnic SLE cohort, especially among patients from middle-income compared with high-income countries and among those with coexistent antiphospholipid syndrome. Increased awareness of cardiovascular disease risk in SLE, especially in the above subgroups, is urgently warranted.
publishDate 2024
dc.date.accessioned.none.fl_str_mv 2024-07-29T22:40:23Z
dc.date.available.none.fl_str_mv 2024-07-29T22:40:23Z
dc.date.issued.none.fl_str_mv 2024
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
dc.type.spa.spa.fl_str_mv Artículo científico
dc.identifier.citation.eng.fl_str_mv Eleana Bolla, Anne Grete Semb, Anne M Kerola, Eirik Ikdahl, Michelle Petri, Guillermo J Pons-Estel, George A Karpouzas, Petros P Sfikakis, Rosana Quintana, Durga Prasanna Misra, Eduardo Ferreira Borba, Ignacio Garcia-de la Torre, Tatiana V Popkova, Bahar Artim-Esen, Anne Troldborg, Hilda Fragoso-Loyo, Sofia Ajeganova, Ayten Yazici, Gustavo Aroca-Martinez, Haner Direskeneli, Manuel F Ugarte-Gil, Marta Mosca, Mohit Goyal, Elisabet Svenungsson, Carla Macieira, Alberta Hoi, Karoline Lerang, Nathalie Costedoat-Chalumeau, Angela Tincani, Erkin Mirrakhimov, Isabel Acosta Colman, Alvaro Danza, Loreto Massardo, Jelena Blagojevic, Neslihan Yılmaz, Dana Tegzová, Sule Yavuz, Cengiz Korkmaz, Eric Hachulla, Mario J Moreno Alvarez, Roberto Muñoz-Louis, Nikos Pantazis, Maria G Tektonidou, Veronica Bellomio, Ilaria Cavazzana, Nikita Khmelinskii, Odirlei Andre Monticielo, Margarita Portela Hernández, Miguel Angel Saavedra Salinas, Marina Scolnik, Ana Carolina Silva Montandon, Esin Yilmaz, Dina Zucchi, Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries, The Lancet Rheumatology, Volume 6, Issue 7, 2024, Pages e447-e459, ISSN 2665-9913, https://doi.org/10.1016/S2665-9913(24)00090-0.
dc.identifier.issn.none.fl_str_mv 26659913 (En línea)
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12442/14939
dc.identifier.doi.none.fl_str_mv doi.org/10.1016/ S2665-9913(24)00090-0
dc.identifier.url.none.fl_str_mv https://www.sciencedirect.com/science/article/abs/pii/S2665991324000900?via%3Dihub
identifier_str_mv Eleana Bolla, Anne Grete Semb, Anne M Kerola, Eirik Ikdahl, Michelle Petri, Guillermo J Pons-Estel, George A Karpouzas, Petros P Sfikakis, Rosana Quintana, Durga Prasanna Misra, Eduardo Ferreira Borba, Ignacio Garcia-de la Torre, Tatiana V Popkova, Bahar Artim-Esen, Anne Troldborg, Hilda Fragoso-Loyo, Sofia Ajeganova, Ayten Yazici, Gustavo Aroca-Martinez, Haner Direskeneli, Manuel F Ugarte-Gil, Marta Mosca, Mohit Goyal, Elisabet Svenungsson, Carla Macieira, Alberta Hoi, Karoline Lerang, Nathalie Costedoat-Chalumeau, Angela Tincani, Erkin Mirrakhimov, Isabel Acosta Colman, Alvaro Danza, Loreto Massardo, Jelena Blagojevic, Neslihan Yılmaz, Dana Tegzová, Sule Yavuz, Cengiz Korkmaz, Eric Hachulla, Mario J Moreno Alvarez, Roberto Muñoz-Louis, Nikos Pantazis, Maria G Tektonidou, Veronica Bellomio, Ilaria Cavazzana, Nikita Khmelinskii, Odirlei Andre Monticielo, Margarita Portela Hernández, Miguel Angel Saavedra Salinas, Marina Scolnik, Ana Carolina Silva Montandon, Esin Yilmaz, Dina Zucchi, Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries, The Lancet Rheumatology, Volume 6, Issue 7, 2024, Pages e447-e459, ISSN 2665-9913, https://doi.org/10.1016/S2665-9913(24)00090-0.
26659913 (En línea)
doi.org/10.1016/ S2665-9913(24)00090-0
url https://hdl.handle.net/20.500.12442/14939
https://www.sciencedirect.com/science/article/abs/pii/S2665991324000900?via%3Dihub
dc.language.iso.none.fl_str_mv eng
language eng
dc.rights.eng.fl_str_mv Attribution-NonCommercial-NoDerivs 3.0 United States
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.rights.accessrights.none.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivs 3.0 United States
http://creativecommons.org/licenses/by-nc-nd/3.0/us/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.mimetype.none.fl_str_mv pdf
dc.publisher.eng.fl_str_mv Elsevier
dc.source.eng.fl_str_mv The Lancet Reumatología
dc.source.none.fl_str_mv Vol. 6 No. 7, (2024)
institution Universidad Simón Bolívar
bitstream.url.fl_str_mv https://bonga.unisimon.edu.co/bitstreams/bfc4289f-3651-4a05-baa7-61f134c577da/download
https://bonga.unisimon.edu.co/bitstreams/73e8abf3-c0a5-4b2e-a71f-bf71a9ac3be6/download
https://bonga.unisimon.edu.co/bitstreams/2f7d7b11-1632-48cd-a08c-b57001cd3b0b/download
https://bonga.unisimon.edu.co/bitstreams/76c34af5-48eb-49e5-886b-cd0cbc065a36/download
bitstream.checksum.fl_str_mv 2f656a26de8af8c32aaacd5e2a33538c
733bec43a0bf5ade4d97db708e29b185
801e41cd66cda4f4dce21dbe27b023cd
1320e29bc3a02e15ae65912d91d6347d
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv repositorio.digital@unisimon.edu.co
_version_ 1812100475812577280
spelling Bolla, Eleana81a37190-1d9e-4e4e-b344-a10901256ef9-1Semb, Anne Gretee57dd701-38df-4346-a46a-b44c8d17051b-1Kerola, Anne M.307c6c44-0474-4383-8de9-72843bbb962b-1Ikdahl, Eirik81516485-a185-4307-a9c4-d12f6b400fb9-1Petri, Michelle7cf5393d-3c56-4f18-86e6-31dffecf2045-1Pons-Estel, Guillermo J.8facffa5-afa8-4019-9b99-273c3160898b-1Karpouzas, George A.33f71516-9f65-44df-96c9-77a187f63ed7-1Sfikakis, Petros P.fe34af0f-2b6e-4681-993c-0b3c25a7b665-1Quintana, Rosana430a53ef-9412-4137-a81c-455b531e2cd4-1Prasanna Misra, Durga2362c17f-9675-41d0-8ae4-3eb8f2f11205-1Ferreira Borba, Eduardoc04a84e8-e8a4-47da-9942-18cfb30cc487-1Garcia-de la Torre, Ignacio95daeb58-3503-4342-807d-85c38ea9b56e-1Popkova, Tatiana V.c82c3ee8-c551-4d61-91e6-aa72ce4ce49f-1Artim-Esen, Bahar82adfc5f-43b7-4ed2-a155-22e7cb0a5d87-1Troldborg, Anneb346fba2-b2cb-493a-93b2-6c6aa3cec205-1Fragoso-Loyo, Hilda7f9a5f6f-66ef-4190-aad7-6d6c0efda7ef-1Ajeganova, Sofiac8484a1a-4bff-4241-8179-5737a695a49b-1Yazici, Ayten9a8f2eda-bc7c-4b61-9c33-1ab805e6d8b5-1Aroca-Martinez, Gustavo9ebd2f8e-91b1-462f-a15a-09db2a45ce2b-1Direskeneli, Haner597066c3-334b-4161-8b6f-633d95e00f26-1Ugarte-Gil, Manuel F.bdccb440-9353-4daf-b21a-331c1c4148ff-1Mosca, Marta41d63dfd-dbe0-437c-9ce9-c808cedc6e13-1Goyal, Mohit97cf3bdf-f9a8-48bb-885b-cc55e0bcffa9-1Svenungsson, Elisabet43e33bd6-917e-4c78-9c7d-aa06ab3fc889-1Macieira, Carla8f484c00-1fba-406e-8101-44d371b351b6-1Hoi, Alberta36332f3f-4ac5-4bbc-9006-8705e5efffd5-1Lerang, Karolineb73baf40-19f7-43d6-bda7-9adf8efa1d01-1Costedoat-Chalumeau, Nathaliedafe9102-13b9-4305-8e6b-162d50623189-1Tincani, Angela7226235f-9cf1-4be1-b697-27af5432e279-1Mirrakhimov, Erkin3cd95395-9400-49e9-a7c3-0cdf577183c6-1Acosta Colman, Isabel4edfabab-679f-4234-b78e-54b6a7a6d33d-1Danza, Alvaro2eaf53f3-9c18-4bd8-b900-b733a4ab0231-1Massardo, Loretoc3f2d6f6-9da6-48db-827a-f30399b6e959-1Blagojevic, Jelena11d3fe8d-5964-4ac9-9aaa-8c1f523f2378-1Yılmaz, Neslihanc32bb070-d0a3-4c38-b531-f5eec738cb10-1Tegzová, Danaf94bdfd0-d976-409e-a1d2-3aec63296b46-1Yavuz, Sule24334ff1-683e-4c0f-83cf-73a476787615-1Korkmaz, Cengiz4ac7a28e-63af-4aed-b3ef-2fc3affcda16-1Hachulla, Eric4568669f-402c-463c-9d28-a50d1e9e85e5-1Moreno Alvarez, Mario J.34094202-0f47-446d-8236-26d10b2d144e-1Muñoz-Louis, Robertoc33b3983-4d63-4a75-a522-da9631224555-1Pantazis, Nikos241d310a-8b13-42a8-b343-272876ffc6db-1Tektonidou, Maria G.e4ecb3cd-19bf-47d0-80d2-f1ba9c1300bb-1behalf of the SURF-SLE and APS83ea0571-1499-4c27-8172-fdd2a2b6ad1a-12024-07-29T22:40:23Z2024-07-29T22:40:23Z2024Eleana Bolla, Anne Grete Semb, Anne M Kerola, Eirik Ikdahl, Michelle Petri, Guillermo J Pons-Estel, George A Karpouzas, Petros P Sfikakis, Rosana Quintana, Durga Prasanna Misra, Eduardo Ferreira Borba, Ignacio Garcia-de la Torre, Tatiana V Popkova, Bahar Artim-Esen, Anne Troldborg, Hilda Fragoso-Loyo, Sofia Ajeganova, Ayten Yazici, Gustavo Aroca-Martinez, Haner Direskeneli, Manuel F Ugarte-Gil, Marta Mosca, Mohit Goyal, Elisabet Svenungsson, Carla Macieira, Alberta Hoi, Karoline Lerang, Nathalie Costedoat-Chalumeau, Angela Tincani, Erkin Mirrakhimov, Isabel Acosta Colman, Alvaro Danza, Loreto Massardo, Jelena Blagojevic, Neslihan Yılmaz, Dana Tegzová, Sule Yavuz, Cengiz Korkmaz, Eric Hachulla, Mario J Moreno Alvarez, Roberto Muñoz-Louis, Nikos Pantazis, Maria G Tektonidou, Veronica Bellomio, Ilaria Cavazzana, Nikita Khmelinskii, Odirlei Andre Monticielo, Margarita Portela Hernández, Miguel Angel Saavedra Salinas, Marina Scolnik, Ana Carolina Silva Montandon, Esin Yilmaz, Dina Zucchi, Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries, The Lancet Rheumatology, Volume 6, Issue 7, 2024, Pages e447-e459, ISSN 2665-9913, https://doi.org/10.1016/S2665-9913(24)00090-0.26659913 (En línea)https://hdl.handle.net/20.500.12442/14939doi.org/10.1016/ S2665-9913(24)00090-0https://www.sciencedirect.com/science/article/abs/pii/S2665991324000900?via%3DihubBackground Systemic lupus erythematosus (SLE) is characterised by increased cardiovascular morbidity and mortality risk. We aimed to examine the prevalence of traditional cardiovascular risk factors and their control in an international survey of patients with systemic lupus erythematosus. Methods In this multicentre, cross-sectional study, cardiovascular risk factor data from medical files of adult patients (aged ≥18) with SLE followed between Jan 1, 2015, and Jan 1, 2020, were collected from 24 countries, across five continents. We assessed the prevalence and target attainment of cardiovascular risk factors and examined potential differences by country income level and antiphospholipid syndrome coexistence. We used the Systemic Coronary Risk Evaluation algorithm for cardiovascular risk estimation, and the European Society of Cardiology guidelines for assessing cardiovascular risk factor target attainment. People with lived experience were not involved in the research or writing process. Findings 3401 patients with SLE were included in the study. The median age was 43·0 years (IQR 33–54), 3047 (89·7%) of 3396 patients were women, 349 (10.3%) were men, and 1629 (48·1%) of 3390 were White. 556 (20·7%) of 2681 patients had concomitant antiphospholipid syndrome. We found a high cardiovascular risk factor prevalence (hypertension 1210 [35·6%] of 3398 patients, obesity 751 [23·7%] of 3169 patients, and hyperlipidaemia 650 [19·8%] of 3279 patients), and suboptimal control of modifiable cardiovascular risk factors (blood pressure [target of <130/80 mm Hg], BMI, and lipids) in the entire SLE group. Higher prevalence of cardiovascular risk factors but a better blood pressure (target of <130/80 mm Hg; 54·9% [1170 of 2132 patients] vs 46·8% [519 of 1109 patients]; p<0·0001), and lipid control (75·0% [895 of 1194 patients] vs 51·4% [386 of 751 patients], p<0·0001 for high-density lipoprotein [HDL]; 66·4% [769 of 1158 patients] vs 60·8% [453 of 745 patients], p=0·013 for non-HDL; 80·9% [1017 of 1257 patients] vs 61·4% [486 of 792 patients], p<0·0001 for triglycerides]) was observed in patients from high-income versus those from middle-income countries. Patients with SLE with antiphospholipid syndrome had a higher prevalence of modifiable cardiovascular risk factors, and significantly lower attainment of BMI and lipid targets (for low-density lipoprotein and non-HDL) than patients with SLE without antiphospholipid syndrome. Interpretation High prevalence and inadequate cardiovascular risk factor control were observed in a large multicentre and multiethnic SLE cohort, especially among patients from middle-income compared with high-income countries and among those with coexistent antiphospholipid syndrome. Increased awareness of cardiovascular disease risk in SLE, especially in the above subgroups, is urgently warranted.pdfengElsevierAttribution-NonCommercial-NoDerivs 3.0 United Stateshttp://creativecommons.org/licenses/by-nc-nd/3.0/us/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2The Lancet ReumatologíaVol. 6 No. 7, (2024)Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countriesinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1Yazdany J, Pooley N, Langham J, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open 2020; 6: e001247.Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 2017; 76: 2009–16.Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013; 43: 77–95.Farina N, Abdulsalam R, McDonnell T, et al. Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events. Rheumatology 2023; 62: 2252–56.Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2022; 81: 768–79.Papazoglou N, Kravvariti E, Konstantonis G, Sfikakis PP, Tektonidou MG. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. Rheumatology 2024; 63: 50–57.Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959–68.Maynard JW, Fang H, Petri M. Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosus. J Rheumatol 2012; 39: 777–83.Rollefstad S, Ikdahl E, Wibetoe G, et al. An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries. Eur Heart J Cardiovasc Pharmacother 2022; 8: 539–48.Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–86.Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315–81.Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48: 3159–67.Urowitz MB, Gladman D, Ibañez D, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 2007; 16: 731–35.Dagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2020; 395: 785–94.Urowitz MB, Gladman DD, Anderson NM, et al. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med 2016; 3: e000143.Urowitz MB, Su J, Gladman DD. Atherosclerotic vascular events in systemic lupus erythematosus: an evolving story. J Rheumatol 2020; 47: 66–71.Saito M, Yajima N, Yanai R, et al. Prevalence and treatment conditions for hypertension and dyslipidaemia complicated with systemic lupus erythematosus: a multi-centre cross-sectional study. Lupus 2021; 30: 1146–53.Tselios K, Gladman DD, Su J, Urowitz M. Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. Ann Rheum Dis 2020; 79: 612–17.Stojan G, Magder LS, Petri M. Blood pressure variability and agerelated blood pressure patterns in systemic lupus erythematosus. J Rheumatol 2020; 47: 387–93.Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021–104Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: 1269–324.Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–88.Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73: 3168–3209Yu HH, Chen PC, Yang YH, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study. Atherosclerosis 2015; 243: 11–18.Taddei C, Zhou B, Bixby H, et al. Repositioning of the global epicentre of non-optimal cholesterol. Nature 2020; 582: 73–77.Tektonidou MG. Cardiovascular disease risk in antiphospholipid syndrome: thrombo-inflammation and atherothrombosis. J Autoimmun 2022; 128: 102813.Bolla E, Tentolouris N, Sfikakis PP, Tektonidou MG. Metabolic syndrome in antiphospholipid syndrome versus rheumatoid arthritis and diabetes mellitus: association with arterial thrombosis, cardiovascular risk biomarkers, physical activity, and coronary atherosclerotic plaques. Front Immunol 2023; 13: 1077166.Bolla E, Tentolouris N, Sfikakis PP, Tektonidou MG. Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus. Lupus Sci Med 2021; 8: e000579.Riancho-Zarrabeitia L, Martínez-Taboada V, Rúa-Figueroa I, et al. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus 2020; 29: 1556–65.ORIGINALCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8905https://bonga.unisimon.edu.co/bitstreams/bfc4289f-3651-4a05-baa7-61f134c577da/download2f656a26de8af8c32aaacd5e2a33538cMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/73e8abf3-c0a5-4b2e-a71f-bf71a9ac3be6/download733bec43a0bf5ade4d97db708e29b185MD53TEXTPDF.pdf.txtPDF.pdf.txtExtracted texttext/plain79481https://bonga.unisimon.edu.co/bitstreams/2f7d7b11-1632-48cd-a08c-b57001cd3b0b/download801e41cd66cda4f4dce21dbe27b023cdMD54THUMBNAILPDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg6454https://bonga.unisimon.edu.co/bitstreams/76c34af5-48eb-49e5-886b-cd0cbc065a36/download1320e29bc3a02e15ae65912d91d6347dMD5520.500.12442/14939oai:bonga.unisimon.edu.co:20.500.12442/149392024-08-14 21:52:30.325http://creativecommons.org/licenses/by-nc-nd/3.0/us/Attribution-NonCommercial-NoDerivs 3.0 United Statesmetadata.onlyhttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.coPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj48aW1nIGFsdD0iTGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyIgc3R5bGU9ImJvcmRlci13aWR0aDowO3dpZHRoOjEwMHB4OyIgc3JjPSJodHRwczovL2kuY3JlYXRpdmVjb21tb25zLm9yZy9sL2J5LW5jLzQuMC84OHgzMS5wbmciIC8+PC9hPjxici8+RXN0YSBvYnJhIGVzdMOhIGJham8gdW5hIDxhIHJlbD0ibGljZW5zZSIgaHJlZj0iaHR0cDovL2NyZWF0aXZlY29tbW9ucy5vcmcvbGljZW5zZXMvYnktbmMvNC4wLyI+TGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyBBdHJpYnVjacOzbi1Ob0NvbWVyY2lhbCA0LjAgSW50ZXJuYWNpb25hbDwvYT4u